Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Lung Neoplasms 147Melanoma 92Squamous Cell Carcinoma of Head and Neck 70Carcinoma, Renal Cell 63Neoplasms 61Colorectal Neoplasms 61Triple Negative Breast Neoplasms 48Neoplasm Metastasis 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Ovarian Neoplasms 42Stomach Neoplasms 39Small Cell Lung Carcinoma 39Pancreatic Neoplasms 39Carcinoma, Transitional Cell 38Breast Neoplasms 38Head and Neck Neoplasms 34Uterine Cervical Neoplasms 30Endometrial Neoplasms 30Urinary Bladder Neoplasms 26Esophageal Neoplasms 24Carcinoma, Hepatocellular 24Mesothelioma 21Mesothelioma, Malignant 18Kidney Neoplasms 15Prostatic Neoplasms 14Adenocarcinoma of Lung 14Carcinoma 13Colonic Neoplasms 12Cholangiocarcinoma 12

Interventions

sotorasib 1pembrolizumab 1lorlatinib 1liposomal doxorubicin 1encorafenib 1cemiplimab 1binimetinib 1berzosertib 1Topotecan 1Taxes 1Paclitaxel 1PX-866 1NVP-BKM120 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × pembrolizumab × Thoracic × Clear all
NCT05128487 2024-11-25

A Study of NDI 1150-101 in Patients With Solid Tumors

Nimbus Therapeutics

Phase 1/2 Active not recruiting
106 enrolled
GenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡